EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Immobilized hirudin and hirudin-based peptides used for the purification of recombinant human thrombin prepared from recombinant human prothrombin



Immobilized hirudin and hirudin-based peptides used for the purification of recombinant human thrombin prepared from recombinant human prothrombin



Protein Expression and Purification 8(2): 167-174



A simple and efficient activation-affinity purification system was developed to obtain thrombin from recombinant CHO cells expressing human prothrombin. In this method, a controllable process for the activation of recombinant prothrombin is directly coupled with a purification strategy for the recombinant thrombin generated. At a constant flow rate and with a contact time limited to few seconds, recombinant prothrombin was filtered through immobilized trypsin. In a closed flow system, the recombinant thrombin generated was filtered through newly designed thrombin-specific affinity gels. Hirudin, the most specific thrombin inhibitor, and hirudin-based peptides were covalently immobilized to Sepharose, thus creating thrombin-specific affinity gels that immediately absorb the thrombin generated from the activation mixture. Prothrombin and incompletely activated molecules did not bind to the affinity gel and were recirculated for a further activation cycle. Due to the specificity of the affinity gels for thrombin and the elimination of thrombin from the activation mixture, proteolytic degradation and autocatalytic inactivation of the recombinant thrombin was prevented. Recombinant thrombin was isolated from the hirudin-based affinity gels by chaotrope salt elution, resulting in high yields of highly pure, active thrombin. Affinity purification of thrombin was not deleteriously affected by contamination of the starting material with other proteins. Activation and affinity purification were equally effective for recombinant and human plasma-derived prothrombin as well as for human and recombinant thrombin.

(PDF emailed within 0-6 h: $19.90)

Accession: 008815600

Download citation: RISBibTeXText

PMID: 8812854

DOI: 10.1006/prep.1996.0089



Related references

Qualitative and quantitative detection of human and recombinant thrombin by binding to leech and recombinant hirudin immobilized at the solid phase. Thrombosis Research 81(1): 157-162, 1996

Measurement of thrombin-hirudin complex documents persistent thrombin formation in patients with unstable angina during anticoagulation with recombinant hirudin. Circulation 88(4 PART 2): I319, 1993

Determination of r DNA hirudin and A-human thrombin- hirudin complex in plasma samples: enzyme linked immunosorbent assays for hirudin and complex vs. chromogenic thrombin substrate assay. Thrombosis Research 66(1): 33-42, 1992

Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin--thrombin interaction. European Journal of Biochemistry 188(2): 463-470, 1990

Chemical modifications and amino acid substitutions in recombinant hirudin that increase hirudin-thrombin affinity. Biochemistry 30(5): 1271-1277, 1991

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. Journal of the American College of Cardiology 22(4): 1080-1088, 1993

The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249(4966): 277-280, 1990

Recombinant hirudin: kinetic mechanism for the inhibition of human thrombin. Protein Engineering 4(3): 295-300, 1991

Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. Thrombosis and Haemostasis 81(2): 250-255, 1999

Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagulation & Fibrinolysis 6(6): 553-560, 1995

Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagulation & Fibrinolysis 5(6): 879-887, 1994

Rational design, recombinant preparation, and in vitro and in vivo characterization of human prothrombin-derived hirudin antagonists. Journal of Biological Chemistry 271(39): 23737-23742, 1996

Inhibition of clot-bound and free by a novel synthetic thrombin inhibitor , recombinant hirudin and heparin in human plasma. Blood Coagulation & Fibrinolysis 5(6): 879-887, 1994

Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. Biochemistry 29(47): 10602-10612, 1990

Degradation of rDNA hirudin and alpha-human thrombin hirudin complex in liver and kidney homogenates from rat. Thrombosis Research 64(6): 763-767, 1991